Drug

Lansoprazole

In clinical development

Emerging researchLate-stage developmentSteady momentum

Also known as Prevacid, Lansoprazol, Lanzoprazole, Lansoprazolum.

RxNorm17128 ChEMBLCHEMBL480UNII0K5C5T2QPG

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Randomized Double-blind, Double Dummy, Active Comparator-controlled Dose-finding Study in Patients With Erosive Esophagitis Due to Gastro-esophageal Reflux Disease (GERD) Los Angeles Grade C or D, and Patients With at Least Partial Symptom Response But Endoscopically Still Unhealed After 8 Weeks History of Standard Treatment Healing Course With Proton-pump Inhibitor (PPI), to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole, and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Clinical trial2026-07-01Results posted · ClinicalTrials.gov

Physiologic Determinants of PPI Disposition in Children

Clinical trial2026-06-04Results posted · ClinicalTrials.gov

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer

Clinical trial2026-04-16Results expected Q4 2027 · ClinicalTrials.gov

Randomized Active-Controlled Trial Evaluating Fexuprazan for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention-Fexuprazan for Patients With Dual Antiplatelet Therapy Trial

Clinical trial2026-04-08Results expected Q2 2028 · ClinicalTrials.gov

The Effectiveness and Risks of Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole: a Randomised Placebo-controlled Multi-centre Clinical Trial

Clinical trial2026-02-28Primary completion · ClinicalTrials.gov

A Comparison of The Effectiveness of Tegoprazan and Lansoprazole in Achieving Cure Rates in Patients With Bleeding Peptic Ulcers: A Double-Blind Randomized Trial

Clinical trial2025-12-31Primary completion · ClinicalTrials.gov

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

Research2012-01-01JAMA

Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Research2010-02-27Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.

Research2009-09-04Alimentary pharmacology & therapeutics

Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Research2009-04-01Alimentary pharmacology & therapeutics

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Lansoprazole

Aliases & brands

PrevacidLansoprazolLanzoprazoleLansoprazolum

RxNorm CUI

17128

ChEMBL ID

CHEMBL480

UNII

0K5C5T2QPG

Clinical trials

137 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

137

registered trials across all phases

LATEST COMPLETION 2025

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 137

Early Phase 11Phase 125Phase 1 / 22Phase 211Phase 2 / 32Phase 340Phase 443Phase N / A13

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer

Not yet recruitingPH IVDaewoong Pharmaceutical Co. LTD.n=3602027

A Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Efficacy of Fexuprazan for the Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids (FEAST)

CompletedPH IVYonsei Universityn=422025

The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control

Unknown statusPH IVDaejeon St. Mary's hospitaln=3002025

Physiologic Determinants of PPI Disposition in Children

CompletedPH IVChildren's Mercy Hospital Kansas Cityn=762024

Vonoprazan Study In Patients With Erosive Esophagitis to Evaluate Long-term Safety: A Study to Evaluate the Safety of Long-term Administration of Vonoprazan in Maintenance Treatment in Patients With Erosive Esophagitis (EE)

CompletedPH IVTakedan=2082022

Recent completions

Trials that read out recently, adding to the completed evidence base.

CompletedPH IVYonsei Universityn=422025

Physiologic Determinants of PPI Disposition in Children

CompletedPH IVChildren's Mercy Hospital Kansas Cityn=762024

A Multi-center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

CompletedPH IIIOnconic Therapeutics Inc.n=3292024

A Randomized, Open-label, 2x2 Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics After Oral Administration of AD-212-A or AD-2121 in Healthy Adult Volunteers

CompletedPH IAddpharma Inc.n=242024

A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer

CompletedPH IIIDaewoong Pharmaceutical Co. LTD.n=4232023

A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Parallel Group Phase III Clinical Study to Evaluate the Efficacy and Safety of X842 Capsules in Patients With Reflux Esophagitis

CompletedPH IIIJiangsu Sinorda Biomedicine Co., Ltdn=3802022

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20092012

Most influential

Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.

JAMA · 2012 · 156 cites

Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.

Alimentary pharmacology & therapeutics · 2009 · 81 cites

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.

Alimentary pharmacology & therapeutics · 2009 · 27 cites

Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2010 · 12 cites